Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) was down 2.4% during trading on Thursday . The company traded as low as $48.21 and last traded at $48.89. Approximately 264,595 shares were traded during mid-day trading, an increase of 40% from the average daily volume of 189,291 shares. The stock had previously closed at $50.08.
Gemini Therapeutics Stock Performance
The company’s fifty day moving average is $45.93 and its two-hundred day moving average is $54.94. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -48.89 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- Stock Average Calculator
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- Business Services Stocks Investing
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
